These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2060254)

  • 21. Polymorphic N-acetylation of a caffeine metabolite.
    Grant DM; Tang BK; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):355-9. PubMed ID: 6825389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interindividual and intraindividual variability in acetylation: characterization with caffeine.
    Hardy BG; Lemieux C; Walker SE; Bartle WR
    Clin Pharmacol Ther; 1988 Aug; 44(2):152-7. PubMed ID: 3396262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylation polymorphism of caffeine in a Japanese population.
    Hashiguchi M; Ebihara A
    Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An alternative test for acetylator phenotyping with caffeine.
    Tang BK; Kadar D; Kalow W
    Clin Pharmacol Ther; 1987 Nov; 42(5):509-13. PubMed ID: 3677540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
    Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of a caffeine test for determining the phenotype of N-acetyltransferase].
    Gascon MP; Leemann T; Dayer P
    Schweiz Med Wochenschr; 1987 Dec; 117(49):1974-6. PubMed ID: 3423781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers.
    Murayama N; Shimizu M; Kobayashi K; Kishimoto I; Yamazaki H
    Drug Metab Lett; 2017; 10(4):240-243. PubMed ID: 27842485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of acetylator phenotype in Caucasians with caffeine.
    Hildebrand M; Seifert W
    Eur J Clin Pharmacol; 1989; 37(5):525-6. PubMed ID: 2598993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe].
    Li J; Peng XQ; Zhang J; Xu JP
    Yao Xue Xue Bao; 2006 Mar; 41(3):282-4. PubMed ID: 16759004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylator phenotypes of Saudi Arabians by a simplified caffeine metabolites test.
    el-Yazigi A; Chaleby K; Martin CR
    J Clin Pharmacol; 1989 Mar; 29(3):246-50. PubMed ID: 2723111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A population and family study of N-acetyltransferase using caffeine urinary metabolites.
    Bechtel YC; Bonaiti-Pellie C; Poisson N; Magnette J; Bechtel PR
    Clin Pharmacol Ther; 1993 Aug; 54(2):134-41. PubMed ID: 8354022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HPLC determination of five caffeine metabolites].
    Lu JF; Yi T; Cao XM; Zhuo HT; Lin SS
    Yao Xue Xue Bao; 1997 Aug; 32(8):607-11. PubMed ID: 11596311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH; Nierenberg DW; Bresnick E
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test.
    Klebovich I; Rautio A; Salonpää P; Arvela P; Pelkonen O; Sotaniemi EA
    Biomed Pharmacother; 1995; 49(5):225-7. PubMed ID: 7579000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.